Publication: Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
dc.contributor.author | Yasunori Watanabe | en_US |
dc.contributor.author | Luiza Mendonça | en_US |
dc.contributor.author | Elizabeth R. Allen | en_US |
dc.contributor.author | Andrew Howe | en_US |
dc.contributor.author | Mercede Lee | en_US |
dc.contributor.author | Joel D. Allen | en_US |
dc.contributor.author | Himanshi Chawla | en_US |
dc.contributor.author | David Pulido | en_US |
dc.contributor.author | Francesca Donnellan | en_US |
dc.contributor.author | Hannah Davies | en_US |
dc.contributor.author | Marta Ulaszewska | en_US |
dc.contributor.author | Sandra Belij-Rammerstorfer | en_US |
dc.contributor.author | Susan Morris | en_US |
dc.contributor.author | Anna Sophia Krebs | en_US |
dc.contributor.author | Wanwisa Dejnirattisai | en_US |
dc.contributor.author | Juthathip Mongkolsapaya | en_US |
dc.contributor.author | Piyada Supasa | en_US |
dc.contributor.author | Gavin R. Screaton | en_US |
dc.contributor.author | Catherine M. Green | en_US |
dc.contributor.author | Teresa Lambe | en_US |
dc.contributor.author | Peijun Zhang | en_US |
dc.contributor.author | Sarah C. Gilbert | en_US |
dc.contributor.author | Max Crispin | en_US |
dc.contributor.other | Siriraj Hospital | en_US |
dc.contributor.other | NIHR Oxford Biomedical Research Centre | en_US |
dc.contributor.other | Diamond Light Source | en_US |
dc.contributor.other | The Wellcome Centre for Human Genetics | en_US |
dc.contributor.other | University of Oxford | en_US |
dc.contributor.other | University of Southampton | en_US |
dc.contributor.other | Nuffield Department of Medicine | en_US |
dc.contributor.other | University of Oxford Medical Sciences Division | en_US |
dc.date.accessioned | 2022-08-04T08:19:13Z | |
dc.date.available | 2022-08-04T08:19:13Z | |
dc.date.issued | 2021-04-28 | en_US |
dc.description.abstract | Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of neutralizing antibodies that they produce appropriately processed and assembled viral antigen that mimics that observed on the SARS-CoV-2 virus. Here, we describe the structure, conformation, and glycosylation of the S protein derived from the adenovirus-vectored ChAdOx1 nCoV-19/AZD1222 vaccine. We demonstrate native-like post-translational processing and assembly, and reveal the expression of S proteins on the surface of cells adopting the trimeric prefusion conformation. The data presented here confirm the use of ChAdOx1 adenovirus vectors as a leading platform technology for SARS-CoV-2 vaccines. | en_US |
dc.identifier.citation | ACS Central Science. Vol.7, No.4 (2021), 594-602 | en_US |
dc.identifier.doi | 10.1021/acscentsci.1c00080 | en_US |
dc.identifier.issn | 23747951 | en_US |
dc.identifier.issn | 23747943 | en_US |
dc.identifier.other | 2-s2.0-85105109368 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/76537 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85105109368&origin=inward | en_US |
dc.subject | Chemical Engineering | en_US |
dc.subject | Chemistry | en_US |
dc.title | Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85105109368&origin=inward | en_US |